Pharmaceutical compounds
View Patent ↗Compounds or their salts having general formulas (I) and (II): wherein s is an integer equal to 1 or 2, A is the radical of a drug that satisfies certain pharmacological tests, C and C 1 are bivalent radicals, and precursors of the radicals B and B 1 satisfy certain pharmacological tests.
1. A compound or its salt having the following general formula (I):
A—B—C—N(O) 2 (I)
wherein:
A=R—T 1 —, wherein
R is the radical of the drug, as defined hereunder, having the formula R—T 1 —Z or
R—T 1 —OZ in which Z is H or C 1 -C 5 alkyl, selected from the following classes:
anti-inflammatory drugs: acetylsalicylic acid, 5-aminoacetylsalicylic acid, carprofen, diclofenac sodium salt, diflunisal, etodolac, flufenamic acid, flunixin, flurbiprofen, ibuprofen, indomethacin, indoprofen, ketoprofen, ketorolac, lornoxicam, loxoprofen, meclofenamic acid, mefenamic acid, meloxicam, mesalamine, naproxen, niflumic acid, olsalazine, piroxicam, salsalate, sulindac, suprofen, tenoxicam, tiaprofenic acid, tolfenamic acid, tolmetin and zomepirac;
bronchodilators drugs: albuterol, carbuterol, clenbuterol, diphylline, etofylline, fenoterol, metaproterenol, pirbuterol, salmeterol and terbutaline;
expectorant drugs: ambroxol, bromexine and guaiacol;
antitumoral drugs: anthramycin, daunorubicin, doxorubicin and epirubicin;
antibiotics drugs: amoxicillin, ampicillin, aztreonam, biapenem, carbenecillin, cefaclor, cefadroxil, cefamandole, cefatrizine, cefoxitin, dicloxacillin, imipenem, meclocycline, methacycline, moxalactam, panipenem, bacampicillin, apicycline, clomocycline and oxytetracycline;
bone resorption inhibitors: alendronic acid, etidronic acid and pamidronic acid;
antidementia drugs: tacrine;
T 1 =(CO), O, S, or NR 1C , wherein R 1C is H, C 1 -C 5 alkyl, or a free valence;
B=—T B —X 2 —T BI wherein
T B and T BI are equal or different, T B is (CO) when T 1 is (CO), O, S, or NR 1C , wherein R 1C is as above defined, T B is O when T 1 is (CO), TBI is (CO) or O;
X 2 is a bivalent bridging group such as the corresponding precursor of B, having the formula Z′—T B —X 2 T BI —Z″ in which Z′, Z″ are independently H or OH, is selected from the following compounds:
Hydroxyacids: ferulic acid (DII), caffeic acid (DV), hydro caffeic acid (DVI), p-coumaric acid (DVII):
C is the bivalent —T C —Y— radical, wherein T C is (CO) when T BI is O, T C is O when T BI is (CO);
Y is a linear or branched (C 1 -C 20 )-alkylenoxy group
2. The compound or salt according to claim 1 , wherein Y is a linear or branched (C 1 -C 6 )-alkylenoxy group.
3. The compound or salt according to claim 1 , wherein the bivalent bridging group X 2 is ferulic acid (DII).
4. The compound or salt according to claim 3 , wherein Y is a linear or branched (C 1 -C 6 )-alkylenoxy group.
5. A drug comprising the compound or salt according to claim 1 , in combination with a pharmaceutically acceptable carrier.
6. A pharmaceutical formulation containing the compound or salt according to claim 1 as an active component.
7. A method for treating oxidative stress dysfunction, said method comprising administering a therapeutically effective amount of the compound or salt according to claim 1 , to a patient in need thereof.